Dominique Cheneval, Ph.D.

Dr. Cheneval has close to twenty-five years experience in the pharmaceutical industry. He has held positions with the pharmaceutical giants Sandoz and Novartis, where he led teams in cutting edge research both in numerous drug discovery programs and compound profiling.

In addition to his research and pre-clinical development activities, he has received training in pharmaceutical development, leadership and business management.
Dr. Cheneval graduated with a Ph.D. in Biochemistry from the Swiss Federal Institute of Technology (ETH, Zürich) and was a Postdoctoral Research Fellow at The Johns Hopkins University School of Medicine (Baltimore, Maryland).

Tania Kastelic, Ph.D.

Dr. Kastelic has twenty years of pharmaceutical industry experience including positions as Postdoctoral Fellow and Research Associate with Sandoz and Novartis Pharma AG (Switzerland). She was involved in several drug discovery projects in the field of inflammation and rheumatoid arthritis.

Dr. Kastelic discovered Novation's novel and unique mRNA modulation technology. She brings to Novation superior research skills, proven by her recognition of the potential of modulating mRNA stability as a therapeutic target of orally active drugs.

Dr. Kastelic has a Ph.D. from the Biochemistry, Cellular and Molecular Biology Program of The Johns Hopkins University School of Medicine (Baltimore, Maryland) and a Master of Science in Chemistry from Simon Fraser University (Burnaby, B.C.).

Gordon J. Politeski

Mr. Politeski is an experienced industry executive who was the founding President and CEO of Biomira Inc., a cancer diagnostics and therapeutics company. During his tenure at Biomira, Mr. Politeski took the Company from its initial financing to the TSE and subsequently to the NASDAQ. Biomira remains one of Canada's premier publicly traded biotech companies.

Mr. Politeski has held a number of senior management positions including President and General Manager of Allergan Pharmaceuticals, Director of the Pharmaceutical Group, Pharmacia, and CEO of Ondine Medical Laser Group. A graduate of the University of Saskatchewan and the Amos Tuck Executive Program at Dartmouth College (Hanover, NH), Mr. Politeski has been active in supporting startup biotechnology companies with management, strategy and financial resources.

Kjell Stenberg, Ph.D.

Dr. Kjell Stenberg is Chief Operating Officer of Medwell Capital (formerly BioMS). From 1975 to 2000, Dr. Stenberg held senior research and management positions at Astra and AstraZeneca (worldwide, is one of the largest pharmaceutical companies), where he was involved in bringing various drugs to market either as Director of Research or Director of Development. He was also Director of Licensing and Alliances for AstraZeneca for over 7 years with responsibilities for the identification, negotiation and management of in-licensing projects.
Dr Stenberg has also been involved with three biotech companies at the level of Founder, CEO or CSO. He holds a Ph.D. from the Karolinska Institute, Sweden, and has published extensively in the field of oncology and cell toxicology.

Shaheen Tejani

Ms. Tejani, MBA, is an experienced venture capitalist and company builder. She has been involved in commercialization of technology and venture capital since 1990 and is founder of Smart Seed Fund, a seed stage technology fund focused on hands on management assistance and financing for technology startups.

Ms. Tejani is involved in microfinance initiatives to reduce poverty and works with Vancity to expand their Microloans program for low income entrepreneurs. She sits on the Board of Novation Pharmaceuticals, Waterstreet Technology, and the Vancouver General Hospital and University of British Columbia Hospital Foundation.